179 related articles for article (PubMed ID: 32455529)
1. Anticancer Ruthenium Complexes with HDAC Isoform Selectivity.
Cross JM; Blower TR; Kingdon ADH; Pal R; Picton DM; Walton JW
Molecules; 2020 May; 25(10):. PubMed ID: 32455529
[TBL] [Abstract][Full Text] [Related]
2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
3. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S
Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912
[TBL] [Abstract][Full Text] [Related]
5. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity.
Porter NJ; Osko JD; Diedrich D; Kurz T; Hooker JM; Hansen FK; Christianson DW
J Med Chem; 2018 Sep; 61(17):8054-8060. PubMed ID: 30118224
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
9. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
10. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
Brindisi M; Senger J; Cavella C; Grillo A; Chemi G; Gemma S; Cucinella DM; Lamponi S; Sarno F; Iside C; Nebbioso A; Novellino E; Shaik TB; Romier C; Herp D; Jung M; Butini S; Campiani G; Altucci L; Brogi S
Eur J Med Chem; 2018 Sep; 157():127-138. PubMed ID: 30092367
[TBL] [Abstract][Full Text] [Related]
11. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.
Brindisi M; Cavella C; Brogi S; Nebbioso A; Senger J; Maramai S; Ciotta A; Iside C; Butini S; Lamponi S; Novellino E; Altucci L; Jung M; Campiani G; Gemma S
Future Med Chem; 2016 Sep; 8(13):1573-87. PubMed ID: 27556815
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of class I HDAC isoform selectivity of largazole analogues.
Kim B; Park H; Salvador LA; Serrano PE; Kwan JC; Zeller SL; Chen QY; Ryu S; Liu Y; Byeon S; Luesch H; Hong J
Bioorg Med Chem Lett; 2014 Aug; 24(16):3728-31. PubMed ID: 25070421
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel histone deacetylase 6 inhibitors with benzyl-triazole as the core skeleton.
Mou Z; Gao J; Miao H; Zhang L; Su L; Wang B; Luan Y
Biosci Trends; 2019 Jul; 13(3):267-272. PubMed ID: 31155552
[TBL] [Abstract][Full Text] [Related]
14. Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors.
Zwick V; Simões-Pires C; Cuendet M
J Enzyme Inhib Med Chem; 2016; 31(sup1):209-214. PubMed ID: 27149362
[TBL] [Abstract][Full Text] [Related]
15. Selective Histone Deacetylase Inhibitors with Anticancer Activity.
Ma N; Luo Y; Wang Y; Liao C; Ye WC; Jiang S
Curr Top Med Chem; 2016; 16(4):415-26. PubMed ID: 26268343
[TBL] [Abstract][Full Text] [Related]
16. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
17. Recent Development of Novel HDAC6 Isoform-selective Inhibitors.
Zhao Y; Liang T; Hou X; Fang H
Curr Med Chem; 2021; 28(21):4133-4151. PubMed ID: 33176627
[TBL] [Abstract][Full Text] [Related]
18. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
19. Cyclometalated Ir(III) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy.
Ye RR; Tan CP; He L; Chen MH; Ji LN; Mao ZW
Chem Commun (Camb); 2014 Sep; 50(75):10945-8. PubMed ID: 25096019
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.
Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
